A61K 2039/844
Liver
Official title: {Liver}
A61K2039/844 (Liver) appears on 32 US grants and 81 published applications in this corpus.
Search patents in A61K- Granted patents
- 32
- Published applications
- 81
- Assignees
- 61
- Inventors
- 189
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2017 | 0 | 2 |
| 2018 | 0 | 1 |
| 2019 | 3 | 8 |
| 2020 | 0 | 10 |
| 2021 | 2 | 16 |
| 2022 | 4 | 9 |
| 2023 | 5 | 11 |
| 2024 | 7 | 16 |
| 2025 | 8 | 3 |
| 2026 | 3 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Intracellular delivery of biomolecules to modify immune response8 Sep 2026US 12,728,163 B2Stemcell Technologies Canada Inc.
- CAR-T cell compositions, methods of use thereof9 Jun 2026US 12,649,774 B2Augusta University Research Institute, Inc.
- T-cell receptor for treating fibrolamellar hepatocellular carcinoma20 Jan 2026US 12,528,853 B2St. Jude Children?S Research Hospital
- Genetically engineered cell and application thereof7 Oct 2025US 12,435,119 B2Crage Medical Co., Limited
- Peptides displayed by HLA for use in immunotherapy against different types of cancers3 Jun 2025US 12,318,407 B2Immatics Biotechnologies GmbH
- Mrna composition for treating cancer, preparation containing the same and use thereof28 May 2026US 2026/0144810 A1Industrial Technology Research Institute
- Vaccines and methods of using the same to treat wnt-related cancer26 Mar 2026US 2026/0083831 A1Geneos Therapeutics, Inc.
- Methods of treating primary liver tumors with natural killer cells expressing a cytotoxic receptor complex12 Mar 2026US 2026/0069530 A1Nkarta, Inc.
- Pharmaceutical Composition, Preparation Method and Use Thereof19 Feb 2026US 2026/0048111 A1PuGong Biotech (Hangzhou) Co., Ltd.
- Immunogenic peptides and their uses in cancer diagnosis and therapy29 Jan 2026US 2026/0028382 A1The Chinese University of Hong Kong
Most cited
By later US patents
- Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers7US 10,400,011 B2Immatics Biotechnologies GmbH · 2019
- Chimeric antigen receptor targeting human NKG2DL and methods of preparing said receptor and pharmaceutical composition3US 11,090,335 B2Nanjing Kaedi Biotherapeutics Ltd. · 2021
- Peptides and combination of peptides for use in immunotherapy against various cancers2US 10,383,896 B2Immatics Biotechnologies GmbH · 2019
- Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers2US 11,180,532 B2Immatics Biotechnologies GmbH · 2021
- Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers2US 11,673,917 B2Immatics Biotechnologies GmbH · 2023